Abstract: Disclosed herein are CMP-associated proteins, collected between 10-12 weeks of gestation, that can be used to stratify the risk of later preeclampsia requiring delivery at <=35 weeks of gestation. For those that screen positive, clustering can be used to further characterize the putative subtype of the preeclampsia. Risk stratification and disease phenotype characterizations such as this can optimize prophylactic and therapeutic interventions.

Abstract: The disclosure herein provides methods, systems, and devices for virtually staining biological tissue for enhanced visualization without use of an actual dye or tag by detecting how each pixel of an unstained tissue image changes in waveform after staining with a certain dye(s) and/or tag(s) or other transformation under a certain electromagnetic radiation source, developing a virtual staining transform based on such detection, and applying such virtual staining transform to an unstained biological tissue to virtually stain the tissue.

Abstract: The disclosure herein provides methods, systems, and devices for virtually staining biological tissue for enhanced visualization without use of an actual dye or tag by detecting how each pixel of an unstained tissue image changes in waveform after staining with a certain dye(s) and/or tag(s) or other transformation under a certain electromagnetic radiation source, developing a virtual staining transform based on such detection, and applying such virtual staining transform to an unstained biological tissue to virtually stain the tissue.

Abstract: Compositions and methods for sample preparation and mass spectrometric analysis of peptide samples obtained from biological samples are provided. The compositions and methods include a tandem column system in which a trap column is in fluid contact with an analytical column such as, for example, a HPLC column. As analytes are eluted from the analytical column, they can be passed to a detector (e.g., a mass spectrometer) for peptide analysis.

Abstract: The disclosure herein provides methods, systems, and devices for virtually staining biological tissue for enhanced visualization without use of an actual dye or tag by detecting how each pixel of an unstained tissue image changes in waveform after staining with a certain dye(s) and/or tag(s) or other transformation under a certain electromagnetic radiation source, developing a virtual staining transform based on such detection, and applying such virtual staining transform to an unstained biological tissue to virtually stain the tissue.

Abstract: Disclosed herein are methods and systems for determining risk of preeclampsia. The system can include (a) a computer comprising: (i) a processor; and (II) a memory, coupled to the processor, the memory storing a module comprising: (1) test data for a sample from a subject including values indicating a quantitative measure of one or more markers; (2) a classification rule which, based on values including the measurements, classifies the subject as being at risk of preeclampsia, wherein the classification rule is configured to have a sensitivity of at least 75%, at least 85% or at least 95%; and (3) computer executable instructions for implementing the classification rule on the test data.

Abstract: The disclosure herein provides methods, systems, and devices for virtually staining biological tissue for enhanced visualization without use of an actual dye or tag by detecting how each pixel of an unstained tissue image changes in waveform after staining with a certain dye(s) and/or tag(s) or other transformation under a certain electromagnetic radiation source, developing a virtual staining transform based on such detection, and applying such virtual staining transform to an unstained biological tissue to virtually stain the tissue.

Abstract: Several embodiments disclosed herein relate to methods of providing an optimized drug therapy that is specialized or customized for an individual subject or a group of subjects based, at least in part, on one or more of the genetic profile of the subject, the pharmacogenomic profile of the subject, and/or evaluation of possible drug-drug interactions. In several embodiments, systems specialized for performing one or more aspects of the methods are provided.

Abstract: Several embodiments disclosed herein relate to methods for calculating a dosing regimen that is tailored specifically to the genetic and metabolic profile of a particular patient. In some embodiments, the dosing regimen is related to administration of the antipsychotic drug clozapine, and the tailoring of the regimen reduces risk of adverse side effects.

Abstract: Several embodiments disclosed herein relate to methods of providing an optimized drug therapy that is specialized or customized for an individual subject or a group of subjects based, at least in part, on one or more of the genetic profile of the subject, the pharmacogenomic profile of the subject, and/or evaluation of possible drug-drug interactions. In several embodiments, systems specialized for performing one or more aspects of the methods are provided.

Abstract: The disclosure herein provides methods, systems, and devices for virtually staining biological tissue for enhanced visualization without use of an actual dye or tag by detecting how each pixel of an unstained tissue image changes in waveform after staining with a certain dye(s) and/or tag(s) or other transformation under a certain electromagnetic radiation source, developing a virtual staining transform based on such detection, and applying such virtual staining transform to an unstained biological tissue to virtually stain the tissue.

Abstract: The disclosure herein provides methods, systems, and devices for virtually staining biological tissue for enhanced visualization without use of an actual dye or tag by detecting how each pixel of an unstained tissue image changes in waveform after staining with a certain dye(s) and/or tag(s) or other transformation under a certain electromagnetic radiation source, developing a virtual staining transform based on such detection, and applying such virtual staining transform to an unstained biological tissue to virtually stain the tissue.

Abstract: The disclosure herein provides methods, systems, and devices for virtually staining biological tissue for enhanced visualization without use of an actual dye or tag by detecting how each pixel of an unstained tissue image changes in waveform after staining with a certain dye(s) and/or tag(s) or other transformation under a certain electromagnetic radiation source, developing a virtual staining transform based on such detection, and applying such virtual staining transform to an unstained biological tissue to virtually stain the tissue.

Abstract: Embodiments of the present invention relate to methods and devices for evaluating a pregnant subject and/or identifying risk of preterm labor in the pregnant subject. The inventors have observed that the initiation of preterm labor or its likelihood in a pregnant patient who has not yet completed 36 weeks gestation can be evaluated by measuring levels of one or more biomarker (marker) that is indicative of labor and/or preterm labor in a sample from the patient.